Clinical trials: Skin Neoplasms, active
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy
The main goal of this study is to investigate the effectiveness and safety of chemotherapy agents in the treatment of participants with BPDCN and to provide comparator arm data to the prospective ELZONRIS registry study…
- Trial name
- NCT07785180
- Testing
- Chemotherapy
- Where
- 67 sites in Denmark, France and 9 more
- Volunteers
- 140 people
- Sponsor
- Stemline Therapeutics, Inc.
Solid Cancer, Gastric (Cardia, Body) Cancer
Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients
In this study, the drug capecitabine is investigated. Capecitabine is commonly used to treat breast, colon, and stomach cancers. Capecitabine is taken in tablet form.
- Conditions
- Solid Cancer, Gastric (Cardia, Body) Cancer, Esophageal Cancer, Colorectal Cancer (CRC)
- Trial name
- ESCAPE (NCT07114627)
- Testing
- Blood sampling for pharmacokinetics
- Where
- Netherlands
- Volunteers
- 66 people
- Sponsor
- Erasmus Medical Center
Metastatic Melanoma
TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma
This is an open-label, phase 1 trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with lymphocyte-depleting chemotherapy and TILs in metastatic melanoma patients.
- Trial name
- TUNINTIL-2 (NCT06961786)
- Testing
- TILT-123, TIL, Cyclophosphamide
- Where
- Denmark
- Volunteers
- 9 people
- Sponsor
- TILT Biotherapeutics Ltd.
Breast Cancer
Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer
Capecitabine combined with pyrotinib is the standard protocol for HR+/HER2+ advanced breast cancer after trastuzumab failure, but the incidence of grade 3 hand-foot-syndrome was 16.4%.
- Trial name
- NCT04646759
- Testing
- Fulvestrant combined with Pyrotinib, Capecitabine combined with Pyrotinib
- Where
- China
- Volunteers
- 516 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Early Breast Cancer, Ductal Breast Carcinoma In Situ
Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer
Hypofractionated breast radiotherapy with concomitant tumor bed boost for early breast cancer or ductal breast carcinoma in situ after partial mastectomy
- Trial name
- HFCBB (NCT06984250)
- Testing
- Hypofractionated Radiation Therapy
- Where
- 2 sites in Taiwan
- Volunteers
- 315 people
- Sponsor
- National Taiwan University Hospital
Breast Cancer, Perimenopause
AMH Dynamic Changes to Predict Ovarian Reserve in Perimenopausal Breast Cancer
This study is a prospective observational cohort study aimed at developing a clinical model based on dynamic changes in anti-Müllerian hormone (AMH) to predict ovarian reserve in perimenopausal women with hormone…
- Conditions
- Breast Cancer, Perimenopause, Ovarian Reserve
- Trial name
- NCT07497191
- Volunteers
- 300 people
- Sponsor
- Shengjing Hospital
Breast Cancer
Exercise Interventions for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
The BENEFIT-Study is a randomized controlled 3-arm intervention trial investigating the currently discussed hypothesis that exercise concomitant to chemotherapy (CTx) may have a beneficial effect on cancer prognosis by boosting…
- Trial name
- BENEFIT (NCT02999074)
- Testing
- Resistance exercise, Aerobic exercise, Usual care during neoadjuvant chemotherapy/Exercise after surgery
- Where
- Germany
- Volunteers
- 183 people
- Sponsor
- German Cancer Research Center
Breast Cancer
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
The purpose of this trial is to inform the future clinical development of the two investigational agents in ER+ breast cancer, LEE011 (CDK4/6 inhibitor) and BYL719 (PI3K-alpha inhibitor).
- Trial name
- NCT01872260
- Testing
- LEE011, Letrozole, BYL719
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 259 people
- Sponsor
- Novartis Pharmaceuticals
Dupuytren Contracture
Trial Comparing Treatment Strategies in Dupuytren's Contracture
Trial is a prospective, randomized, controlled, outcome assessor-blinded, three armed parallel 1:1:1, multicenter trial. The research objective is to determine, which treatment strategy 1) primary percutaneous needle fasciotomy…
- Trial name
- DETECT (NCT03192020)
- Testing
- Percutaneous needle fasciotomy (PNF), Collagenase Clostridium Histolyticum (CCH) 2.9 MG/ML [Xiaflex], Limited fasciectomy (LF)
- Where
- 6 sites in Finland
- Volunteers
- 302 people
- Sponsor
- Tampere University
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Video-Conferenced Stress Management and Relaxation Training (VSMART) For Alabama Breast Cancer Survivors
In a sample of Alabama breast cancer survivors, the proposed study tests the feasibility and acceptability of a stress management program that has been shown to improve health and wellbeing in a general population of patients…
- Trial name
- VSMART (NCT06924788)
- Testing
- Video-Conferenced Stress Management and Relaxation Training (VSMART)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Alabama at Birmingham
Head and Neck Cancer, Breast Cancer
Evaluation of Improved Onboard Patient Imaging
The primary objective of radiation therapy is to deliver a therapeutic dose of radiation precisely to the target while minimizing exposure to healthy surrounding tissues.
- Conditions
- Head and Neck Cancer, Breast Cancer, Upper Gastrointestinal Cancer, Lung Cancer
- Trial name
- NCT06187103
- Testing
- HyperSight Imaging
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Varian, a Siemens Healthineers Company
Metastatic Breast Cancer, HRD-Positive/HER2-Negative Advanced Breast Cancer
Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer
This is a Phase III clinical trial for patients with a specific type of advanced breast cancer that is HER2-negative and has a biomarker called "Homologous Recombination Deficiency (HRD)-positive." The study aims to compare the…
- Trial name
- NCT07371910
- Testing
- Chemotherapy/ADC Regimen, Fluorizoparib, Apatinib
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Pancreas Cancer, Pancreatitis
Pancreas Registry and High Risk Registry
The purpose of this study is to establish a registry of patients with pancreatic diseases. Patients included in the registry may include those with: pancreatic cancer, precancerous lesions of the pancreas, inflammatory lesions of…
- Conditions
- Pancreas Cancer, Pancreatitis, Chronic Pancreatitis, Pancreatic Cyst
- Trial name
- NCT02775461
- Where
- 2 sites in United States
- Volunteers
- 1,368 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Actinic Keratosis (AK)
An Open-Label Pharmacokinetic Study for Patients With Actinic Keratosis on the Upper Extremities or the Face
The research study will evaluate how the body absorbs and reacts to reformulated Levulan Kerastick when applied to actinic keratosis lesions (AKs) on the skin of the forearms or face followed by photodynamic therapy (PDT), a…
- Trial name
- NCT07729579
- Testing
- Investigational drug, Photodynamic therapy
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Hepatocellular Carcinoma, Renal Cell Carcinoma
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
This is a research study of an experimental drug called ACC-1898. ACC-1898 is an oral tyrosine kinase inhibitor (TKI) that blocks several proteins kinases which may help cancer cells grow and spread.
- Conditions
- Hepatocellular Carcinoma, Renal Cell Carcinoma, Thyroid Carcinoma, Medullary, Thyroid Carcinoma Primary Differentiated
- Trial name
- NCT07252661
- Testing
- ACC-1898
- Volunteers
- 40 people
- Sponsor
- AccSalus Biosciences, Inc.
Solid Tumor Malignancy, Breast Cancer
Ataraxis Real-World Clinical Outcomes Registry Linking AI-Based Pathology Scores to Patient Outcomes
The ARC Registry is a large-scale, multi-site, prospective, observational registry. All patients with a solid tumor malignancy who receive Ataraxis testing as part of routine clinical care are eligible for enrollment, which will…
- Trial name
- ARC (NCT07706842)
- Testing
- Ataraxis testing
- Volunteers
- 1,000 people
- Sponsor
- Ataraxis AI, Inc.
Breast Cancer
Longitudinal Impact of Adjuvant Chemotherapy on Functional Status, Comorbidity and Quality of Life
The goal of this study is to increase our understanding of the adjuvant chemotherapy experience in older and younger adults by prospectively describing the longitudinal trajectory of functional status, comorbidity, and quality of…
- Trial name
- NCT01030250
- Where
- United States
- Volunteers
- 238 people
- Sponsor
- City of Hope Medical Center
Unresectable or Metastatic Melanoma
A Study of ST-1898 for Unresectable or Metastatic Melanoma
ST-1898 is a receptor tyrosine kinase (RTK) inhibitor for multi-targets, especially for VEGFR2, c-MET, AXL, PDGFRA, RET, KIT etc.
- Trial name
- NCT06359860
- Testing
- ST-1898 tablets
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Beijing Scitech-Mq Pharmaceuticals Limited
Sezary Syndrome, Ichthyosis, Lamellar
Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD)
Autosomal recessive congenital ichthyoses (ARCI) are monogenic diseases of cornification that correspond to a diffuse abnormality (affecting the entire integument) of epidermal differentiation and therefore of the skin barrier.
- Trial name
- NIPALYMPHO (NCT07477769)
- Testing
- blood sampling
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Breast Cancer, Triple Negative Breast Cancer
Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery
This single arm study aims to evaluate the efficacy and safety of a non-surgical approach, consisting of radiotherapy (RT) alone, for patients who have achieved a complete pathological response (pCR) following neoadjuvant…
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, HER2-positive Breast Cancer, Neoadjuvant Chemotherapy
- Trial name
- BETTY-CRASY (NCT06281210)
- Testing
- Omission of surgical treatment
- Where
- 2 sites in Italy
- Volunteers
- 77 people
- Sponsor
- European Institute of Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.